Aeterna Zentaris Inc. (AEZS)
5.72
0.12 (2.14%)
At close: Aug 08, 2024, 8:00 PM
2.14% (1D)
| Bid | n/a |
| Market Cap | 17.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.31 |
| PE Ratio (ttm) | -2.48 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 7,508 |
| Avg. Volume (20D) | 5,842 |
| Open | 5.50 |
| Previous Close | 5.60 |
| Day's Range | 5.48 - 5.93 |
| 52-Week Range | 0.15 - 9.32 |
| Beta | 2.26 |
About AEZS
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. T...
Industry Biotechnology
Sector Healthcare
IPO Date May 10, 2000
Employees 12
Stock Exchange NASDAQ
Ticker Symbol AEZS
Website https://www.zentaris.com